Medytox Inc.'s Form 4 filing
Evolus, Inc. (EOLS) · filed Feb 6, 2023
- Accession no.
- 0001387131-23-001468
- Filed
- Feb 6, 2023
- Trade date
- Aug 12, 2021-Jan 20, 2023
- Filing delay
- 543 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $408.8K. Open-market sales total $409.0K. It was filed 543 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Medytox Inc.CIK 0001848514 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2021 | Common Stock, $0.00001 par value per share | PPurchaseAcquired | +23,000 | $10.99F2 | +$252,770 | 7,282,500 | Indirect | |
| Aug 13, 2021 | Common Stock, $0.00001 par value per share | PPurchaseAcquired | +14,043 | $11.11F3 | +$156,017.73 | 7,296,543 | Indirect | |
| Jan 20, 2023 | Common Stock, $0.00001 par value per share | SSaleDisposed | −37,043 | $11.04 | −$408,954.72 | 7,259,500 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.88 to $11.10, inclusive. The reporting person undertakes to provide to Evolus, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1 to 2.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.91 to $11.26, inclusive.
Referenced by the price of 1 transaction in Table I.